MAIA Biotechnology, Inc.
$1.49
+4.2%MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -2.1).
Valuation inputs: P/E -2.1, earnings yield N/A, momentum +4.2%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -9.4%, ROIC -6.3%).
Profitability stack: net margin 0.0%, ROE -9.4%, ROIC -6.3%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +75.5%, momentum +4.2%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
MAIA Biotechnology, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
MAIA Biotechnology, Inc. Fair Value Envelope
No Revenue Data
MAIA has not reported any revenue values in the available annual periods.
MAIA Biotechnology, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
MAIA has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
MAIA has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
MAIA has not reported any net profit margin values in the available annual periods.
MAIA Biotechnology, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
MAIA Biotechnology, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
MAIA Biotechnology, Inc. Street Expectations Map
No Target Data
No analyst price targets available for maia.
MAIA Biotechnology, Inc. Insider Positioning
During the last 12 months, insiders have purchased $279K worth of MAIA shares, with no selling activity reported.
3 Months
149.7K
203.78K
0
0.00
+204K
+$204K
3-6 Months
57.2K
70.00K
0
0.00
+70K
+$70K
6-9 Months
4.6K
5.49K
0
0.00
+5K
+$5K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Smith Stan
Director
$176K
Vitoc Vlad
Director, 10 Percent Owner, Officer: Chief Executive Officer
$101K
Gryaznov Sergei
Officer: Chief Scientific Officer
$3K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $279K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
3 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
No Dividend Yield Data
MAIA has not reported any dividend yield values in the available annual periods.
maia Dividend History
Learning Layer
Related Guides
Build conviction on MAIA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.